A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy
What is the purpose of this trial?
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
- Trial withAstra Zeneca
- Start Date10/20/2020
- End Date11/11/2022
- Last Updated07/15/2021
- Study HIC#2000025651